Table 1. Characteristics of BRAFi patient cohort (n = 32).
| Factor | Value | N | % |
| Total Patients | N | 32 | 100% |
| Patient Sex | Female | 12 | 38% |
| Male | 20 | 63% | |
| Age at Trial Start (years) | Mean/Median (range) | 52/57 (23–73) | - |
| Genotype | V600E | 30 | 94% |
| V600K | 2 | 6% | |
| BRAFi | Dabrafenib | 29 | 91% |
| Vemurafenib | 3 | 9% | |
| Active Brain Metastases at Trial Start | No | 15 | 44% |
| Yes | 17 | 56% | |
| Subsequent COMBI* | No | 31 | 97% |
| Yes | 1 | 3% | |
| M-stage | M1a | 1 | 3% |
| M1b | 1 | 3% | |
| M1c | 30 | 94% | |
| Baseline Sum of Diameters (mm) | Mean/Median (range) | 127/108(9–317) | - |
| ECOG | 0 | 15 | 47% |
| 1 | 17 | 53% | |
| LDH | Normal | 15 | 47% |
| Elevated | 17 | 53% | |
| Best CT Response | PD | 1 | 3% |
| SD | 8 | 25% | |
| PR | 23 | 72% | |
| CR | 0 | 0% | |
| Progression Status | Progressed | 29 | 94% |
| Not progressed | 3 | 6% | |
| BRAFi Status | Continuing BRAFi | 28 | 88% |
| Not on BRAFi | 4 | 13% | |
| Treatment Beyond Progression∧ | No | 17 | 53% |
| Yes | 15 | 47% | |
| Treatment Beyond Progression (days) | Mean/Median (range) | 116/66 (32–382) | - |
| Last Follow-up Status | Dead | 22 | 72% |
| Alive | 10 | 28% | |
| Follow-up (weeks)* | Mean/Median (range) | 51/41 (8–153) | - |
Abbreviations: PD,progressive disease; SD, stable disease; PR, partial response; CR, complete response.
*COMBI denotes subsequent enrolment in a clinical trial comparing combination BRAFi plus MEK inhibitor to placebo. Follow-up for subsequent COMBI patients (n = 1) was censored at date of cessation of mono-BRAFi.
∧Treatment beyond progression classified as cessation of BRAFi greater than 30 days after date of progression.